Yong Jiang, Le Fan, Yunxia Chai, Feng Xiao, Nan Zhu, Bin Yi
{"title":"新型双靶向改性聚酯白蛋白纳米载体包封lenvatinib后可提高肝癌预后的疗效。","authors":"Yong Jiang, Le Fan, Yunxia Chai, Feng Xiao, Nan Zhu, Bin Yi","doi":"10.1177/08853282251374426","DOIUrl":null,"url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is one of the most common malignant tumors. Lenvatinib (LEN) is a potentially effective HCC-targeted drug, but poor water solubility, rapid metabolism, drug resistance, and clinical side effects hinder its satisfactory efficacy. In this study, we proposed to prepare a novel epithelial cell adhesion molecule (EpCAM)/Vimentin dual-targeting modified polyester albumin nanocarriers to load LEN (EpCAM/Vimentin-LEN-ANs) to improve the therapeutic efficacy of the drug for HCC. The results showed that the EpCAM/Vimentin-LEN-ANs had a particle size of (236.08 ± 6.39) nm, a potential of (38.93 ± 7.15) mv, and were characterized by nanovesicles, with an encapsulation rate of (97.57 ± 2.43) % and a drug loading capacity of (11.16 ± 1.75) %. EpCAM/Vimentin-LEN-ANs can specifically target HCC cells and slowly release LEN drugs, thus effectively inhibiting the growth of HCC cells; in addition, they have good anti-tumor effects and biosafety in vivo. In this study, EpCAM/Vimentin-LEN-ANs were successfully prepared, which can carry LEN and then target into HCC cells to achieve precise delivery and release of drugs, improve anti-tumor efficacy and alleviate the toxic side effects of anti-tumor drugs on the organism, which has a better potential for application and clinical translation in the treatment of HCC.</p>","PeriodicalId":15138,"journal":{"name":"Journal of Biomaterials Applications","volume":" ","pages":"8853282251374426"},"PeriodicalIF":2.5000,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Novel dual-targeted modified polyester albumin nano-carriers enhance the efficacy of hepatocellular carcinoma outcomes after encapsulating lenvatinib.\",\"authors\":\"Yong Jiang, Le Fan, Yunxia Chai, Feng Xiao, Nan Zhu, Bin Yi\",\"doi\":\"10.1177/08853282251374426\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Hepatocellular carcinoma (HCC) is one of the most common malignant tumors. Lenvatinib (LEN) is a potentially effective HCC-targeted drug, but poor water solubility, rapid metabolism, drug resistance, and clinical side effects hinder its satisfactory efficacy. In this study, we proposed to prepare a novel epithelial cell adhesion molecule (EpCAM)/Vimentin dual-targeting modified polyester albumin nanocarriers to load LEN (EpCAM/Vimentin-LEN-ANs) to improve the therapeutic efficacy of the drug for HCC. The results showed that the EpCAM/Vimentin-LEN-ANs had a particle size of (236.08 ± 6.39) nm, a potential of (38.93 ± 7.15) mv, and were characterized by nanovesicles, with an encapsulation rate of (97.57 ± 2.43) % and a drug loading capacity of (11.16 ± 1.75) %. EpCAM/Vimentin-LEN-ANs can specifically target HCC cells and slowly release LEN drugs, thus effectively inhibiting the growth of HCC cells; in addition, they have good anti-tumor effects and biosafety in vivo. In this study, EpCAM/Vimentin-LEN-ANs were successfully prepared, which can carry LEN and then target into HCC cells to achieve precise delivery and release of drugs, improve anti-tumor efficacy and alleviate the toxic side effects of anti-tumor drugs on the organism, which has a better potential for application and clinical translation in the treatment of HCC.</p>\",\"PeriodicalId\":15138,\"journal\":{\"name\":\"Journal of Biomaterials Applications\",\"volume\":\" \",\"pages\":\"8853282251374426\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-09-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Biomaterials Applications\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.1177/08853282251374426\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ENGINEERING, BIOMEDICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biomaterials Applications","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1177/08853282251374426","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
Novel dual-targeted modified polyester albumin nano-carriers enhance the efficacy of hepatocellular carcinoma outcomes after encapsulating lenvatinib.
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors. Lenvatinib (LEN) is a potentially effective HCC-targeted drug, but poor water solubility, rapid metabolism, drug resistance, and clinical side effects hinder its satisfactory efficacy. In this study, we proposed to prepare a novel epithelial cell adhesion molecule (EpCAM)/Vimentin dual-targeting modified polyester albumin nanocarriers to load LEN (EpCAM/Vimentin-LEN-ANs) to improve the therapeutic efficacy of the drug for HCC. The results showed that the EpCAM/Vimentin-LEN-ANs had a particle size of (236.08 ± 6.39) nm, a potential of (38.93 ± 7.15) mv, and were characterized by nanovesicles, with an encapsulation rate of (97.57 ± 2.43) % and a drug loading capacity of (11.16 ± 1.75) %. EpCAM/Vimentin-LEN-ANs can specifically target HCC cells and slowly release LEN drugs, thus effectively inhibiting the growth of HCC cells; in addition, they have good anti-tumor effects and biosafety in vivo. In this study, EpCAM/Vimentin-LEN-ANs were successfully prepared, which can carry LEN and then target into HCC cells to achieve precise delivery and release of drugs, improve anti-tumor efficacy and alleviate the toxic side effects of anti-tumor drugs on the organism, which has a better potential for application and clinical translation in the treatment of HCC.
期刊介绍：
The Journal of Biomaterials Applications is a fully peer reviewed international journal that publishes original research and review articles that emphasize the development, manufacture and clinical applications of biomaterials.
Peer-reviewed articles by biomedical specialists from around the world cover:
New developments in biomaterials, R&D, properties and performance, evaluation and applications
Applications in biomedical materials and devices - from sutures and wound dressings to biosensors and cardiovascular devices
Current findings in biological compatibility/incompatibility of biomaterials
The Journal of Biomaterials Applications publishes original articles that emphasize the development, manufacture and clinical applications of biomaterials. Biomaterials continue to be one of the most rapidly growing areas of research in plastics today and certainly one of the biggest technical challenges, since biomaterial performance is dependent on polymer compatibility with the aggressive biological environment. The Journal cuts across disciplines and focuses on medical research and topics that present the broadest view of practical applications of biomaterials in actual clinical use.
The Journal of Biomaterial Applications is devoted to new and emerging biomaterials technologies, particularly focusing on the many applications which are under development at industrial biomedical and polymer research facilities, as well as the ongoing activities in academic, medical and applied clinical uses of devices.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
